Final Debarment Order: Rahim Shafa; Denial of Hearing
FDA issued a final debarment order against Rahim Shafa, denying a hearing, which prohibits him from providing services to FDA-regulated drug manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that might employ or contract with Rahim Shafa. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately upon publication (no specific deadline provided).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Rahim Shafa is now debarred by the FDA, meaning he cannot provide any services to FDA-regulated drug manufacturers, including consulting, manufacturing, or other services.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing facilities (503B) that might employ or contract with Rahim Shafa.
What you must do
Review current and prospective relationships with Rahim Shafa to ensure he is not providing services to your company; if he is, terminate those arrangements immediately.
Deadline
Immediately upon publication (no specific deadline provided).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- 5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight - Law360
- FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models - BioSpace
- FDA Proposes Foreign Manufacturing Establishment Registration and Product Listing Requirements - regulatoryoversight.com
- Experimental Drugs Without FDA Approval Are Now Legal in Montana - vice.com
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities